Shin Nippon Biomedical Laboratories was among the investors in its spinoff, which is working on treatments for acute migraine.
Satsuma Pharmaceuticals, a US-based acute migraine treatment developer, received $62m in series B funding yesterday from investors including contract research firm Shin Nippon Biomedical Laboratories.
Wellington Management Company led the round, which also featured SBI Investment, a subsidiary of financial services firm SBI, as well as Osage University Partners, RA Capital Management, TPG Biotech, Cam Capital, Surveyor Capital, Eventide Asset Management, Cormorant and Lumira Ventures.
Spun out of Shin Nippon Biomedical Laboratories in 2016, Satsuma is working on a medical…
